• eng
  • ru
The official language of the conference is English
4th Sechenov
Biomedical Summit
(SIBS 2020)
November 17-18, 2020
Sechenov University
Moscow, Russia


... Read more


Deputy Director of the Laboratory of Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing

Dr. Xing-Jie Liang got his Ph.D at National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences. He finished his postdoc with Dr. Michael M. Gottesman (Deputy Director of NIH, USA and Academician member of US national academy of sciences) for 5 years at Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Then, he worked as a Research Fellow at Surgical Neurology Branch, NINDS (National Institute of Neurological Diseases and Strokes, NIH) for 2 years. In 2007, he was an Assistant professor at Department of Radiology, School of Medicine, Howard University. Dr. Liang currently is deputy director of Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and Lab Chief of Laboratory of Controllable Nanopharmaceuticals, National Center for Nanoscience and Technology of China. He is also leading a group on nanopharmaceuticals at the CAS Center for Excellence in Nanoscience and Chief Lecture Professor of Nanobiology at University of Chinese Academy of Sciences.

Dr. Xing-Jie Liang is current editor-in-chief of “Current Drug Delivery”, deputy Editor-in-Chief of “Biophysics Reports” and Associate Editor of “Biomaterials”, Advisory Board Member of “ACS Nano”. He is also current editorial board member of “Bioconjugate Chemistry”, “Biomaterials Research”, “Theranostics” and guest editor of “Biotechnology Advances”.

Dr. Liang was awarded with the Distinguished Young Scientists Grant by National Natural Science Foundation in 2012 and honored with the People's Republic of China State Council Special Allowance in 2010 as well as National Youth Science and technology innovation leader in 2017. Prof. Liang published over 280 peer-reviewed papers including articles in “Nature Nanotechnology, PNAS, Nano Letter, Advanced Materials, Cancer Research” with citations over 13000 until 2018.

The current researches include three topics ongoing in the laboratory.

  1. Nanopharmaceutical techniques: FDA approved materials developed with nanotechnologies to improve the bioavailability and therapeutic efficacy as well as to decrease systemic toxicity of chemocompounds or bio-drugs (genes or proteins) by targeted delivery and controllable release;
  2. Nanobiotechnology: Nanostructures to overcome the adaptive treatment tolerance (ATT) in vitro and in vivo:
  3. Nanoplatforms: Nanoscale DDS for Chemo-/Gene-Therapy; Nano-AIE for Pharmadynamic/Kinetic evaluation; Nanovaccine for immunological enhance of neoantigen:

In addition, another topic on nanoimaging is another interested field in his group.

  1. Nanoimaging and Nanodiagnosis: Nanopharmaceuticals ADMET in vivo by various techniques (Nano SPECT/CT, Acoustic ultrasound, In vivo Imaging, MRI, Bio-TEM etc)


Contact us

Participation in the Summit
Yulia Bikulova, Ekaterina Markova
+7 (499) 390-34-38, +7 (926) 848-23-58
e-mail: sechenov-sibs@confreg.org

Participation in the exhibition:
Daria Andreeva
Tel.: +7 (926) 891 76 23
E-mail: sibs.summit@yandex.ru

We use cookies to improve our website. You agree to our use of cookies by pushing the “Accept Cookies” button and continuing to use our website. To find out more, including how to change your settings, see our Cookie Policy. Accept Cookies